Abstract 671P
Background
Fibroblast activation protein (FAP) is highly expressed on the surface of cancer-associated fibroblasts and has limited expression in normal tissues. [177Lu]Lu-FAP-2286, an investigational radioligand therapy, has shown antitumor activity in preclinical models. LuMIERE is a phase 1/2 open-label study of [177Lu]Lu-FAP-2286 in patients (pts) with advanced FAP-expressing solid tumors.
Methods
Eligible pts for phase 1 had advanced/metastatic solid tumors, were refractory to or had progressed following prior therapy, and had [68Ga]Ga-FAP-2286 uptake in tumoral lesions (PET imaging). A Bayesian optimal interval design included 4 dose escalation levels (starting dose 3.7 GBq; maximum dose 9.25 GBq). Pts received ≤6 cycles every 6 weeks. Dosimetry and safety were assessed after each dose. Primary endpoints were dose-limiting toxicities (DLTs), adverse events (AEs), and clinical laboratory abnormalities. Efficacy was investigator-assessed objective response by RECIST v 1.1.
Results
Of 35 pts enrolled and imaged, 27 were treated (median age 60 years; 52% male). The most common tumors were pancreatic (n=9), colorectal (n=4), and head and neck (n=3). Overall, 14 pts experienced treatment-related AEs, with Grade ≥3 events observed in 2 pts (one event each). Two DLTs were observed: Grade 4 lymphopenia (dose 5.55 GBq; Grade 2 at screening) and Grade 3 hemoptysis (dose 9.25 GBq; lung metastases containing pseudoaneurysms at screening). There were no Grade ≥3 decreases in neutrophil, hemoglobin, or platelet levels over time. Overall, 1 Grade ≥3 AE was reported following imaging with [68Ga]Ga-FAP-2286 (small intestine obstruction), which was not considered treatment related. Best response included partial response in 1 pt and stable disease in 9 pts. The recommended phase 2 dose of [177Lu]Lu-FAP-2286 was declared as 9.25 GBq. Dosimetry data will be presented at ESMO.
Conclusions
[177Lu]Lu-FAP-2286 was well tolerated in heavily pretreated pts with a low incidence of DLTs and Grade ≥3 AEs observed, supporting the commencement of phase 2 and planned combination therapies.
Clinical trial identification
NCT04939610.
Editorial acknowledgement
Medical writing support (including development of a draft outline and subsequent drafts in consultation with the authors, collating author comments, copyediting, and fact checking) was provided by Ryan Riley, PhD at Aspire Scientific (Bollington, UK).
Legal entity responsible for the study
Advanced Accelerator Applications, a Novartis company
Funding
Advanced Accelerator Applications, a Novartis company.
Disclosure
J. McConathy: Financial Interests, Research Funding: Cytosite Biopharma, GE Healthcare, Eli Lilly; Financial Interests, Other, Consulting: Blue Earth Diagnostics, GE Healthcare, Eli Lilly, ImaginAb, Novartis, Telix. Y. Menda: Financial Interests, Research Funding, To the institution: Novartis, Perspective Therapeutics, Fusion Pharmaceuticals; Financial Interests, Advisory Board, To the institution: Progenics Pharmaceuticals. J. Rodon: Financial Interests, Personal, Advisory Board: Ellipses Pharma, iOnctura SA, Aadi Bioscience, Envision Pharma, Molecular Partners, Mekanistic, Amgen; Financial Interests, Personal, Other, Consultancy: Clarion Healthcare, Debiopharm, Cullgen, Pfizer, Macrogenics, Oncology One, Columbus Venture Partners, Sardona Therapeutics, Avoro Capital Advisors, Vall d'Hebron Institute of Oncology/Ministero De Empleo Y Seguridad, Chinese University of Hong Kong, Boxer Capital, Llc, Tang Advisors, Llc, Alnylam Pharmaceuticals, Bridgebio Pharma; Financial Interests, Personal, Other, Consultancy/Advisory Board: Monte Rosa Therapeutics, Merus N.V., Incyte; Financial Interests, Institutional, Other, Clinical Research: Novartis, Spectrum Pharmaceuticals, Symphogen, BioAtla, Pfizer, GenMab, CytomX, Kelun-Biotech, Takeda-Millenium, GSK; Financial Interests, Institutional, Other, Research Funding: Blueprint Medicines, Black Diamond, Merck Sharp & Dohme; Financial Interests, Institutional, Research Grant, Research Funding/Clinical Research: Hummingbird, Yingli; Financial Interests, Institutional, Research Grant, Research Funding: Vall d'Hebron Institute of Oncology/Cancer Core Europe; Financial Interests, Institutional, Research Grant, Clinical Research: Bicycle Therapeutics, Taiho, Roche Pharmaceuticals, Merus, Curis, AadiBioscience, Nuvation, ForeBio, BioMed Valley Discoveries, Loxo Oncology, Cellestia, Deciphera, Ideaya, Amgen, Tango Therapeutics, Mirati, Linnaeus Therapeutics, Bayer, Hutchinson MediPharma; Other, Other: VHIO/Ministero De Empleo Y Seguridad Social; Other, Travel: European Society for Medical Oncology, Loxo Oncology. A.H. Goenka: Financial Interests, Research Grant, PI on institutional research grant: Sofie Biosciences, Novartis; Financial Interests, Other, Consulting: Bayer Healthcare Llc, Candel Therapeutics, UWorld; Financial Interests, Research Grant, Research grants: NIH; Financial Interests, Research Grant: Mayo Clinic Comprehensive Cancer Center, Champions of Hope Pancreatic Cancer Research Program of the Funk Zitiello Foundation, Centene Charitable Foundation, Hoveida Family Foundation. R.H. Moy: Financial Interests, Advisory Board, and consulting: Ideaya Biosciences, Nimbus Therapeutics, PreTech Health ; Financial Interests, Research Funding: Nimbus Therapeutics, Repare Therapeutics. S. Morse: Financial Interests, Other, Employee: Novartis. A. Demange: Financial Interests, Other, Employee: Advanced Accelerator Applications, a Novartis Company; Financial Interests, Stocks/Shares, Stock and stock options: Novartis. P. Aimone: Financial Interests, Other, Employee: Novartis. T.A. Hope: Financial Interests, Research Grant, Grant funding to the institution: Clovis Oncology, GE Healthcare, Janssen, Lantheus, Novartis, Telix Pharmaceuticals, National Cancer Institute, Prostate Cancer Foundation; Financial Interests, Other, Personal fees: Bayer, Blue Earth Diagnostics, Cardinal Health, Lantheus, RayzeBio; Financial Interests, Other, Equity interest in: AdvanCell, Curium.
Resources from the same session
621P - Phase II trial of encorafenib and binimetinib (E+B) in patients (pts) with BRAF-altered advanced solid tumors: Results of E+B cohort in the BELIEVE trial (NCCH1901)
Presenter: Yoshitaka Honma
Session: Poster session 01
622P - Safety and efficacy of ifebemtinib (IN10018) combined with D-1553 in solid tumors with KRAS G12C mutation: Results from a phase Ib/II study
Presenter: Zhengbo Song
Session: Poster session 01
624P - Belvarafenib in patients (pts) with BRAF class II or III alteration-positive tumours: TAPISTRY study
Presenter: Rafal Dziadziuszko
Session: Poster session 01
625P - Initial results from the phase I, first-in-human study of the covalent, PI3Kα inhibitor TOS-358 in patients with solid tumors, expressing PI3Kα mutations or amplifications
Presenter: Marwan Fakih
Session: Poster session 01
626P - Roginolisib (IOA-244), a first oral allosteric modulator of phosphoinositide 3-kinase inhibitor delta (PI3Kδ) in patients with metastatic uveal melanoma
Presenter: Anna Di Giacomo
Session: Poster session 01
627P - Long-term efficacy and safety of larotrectinib in non-primary central nervous system (CNS) TRK fusion cancer
Presenter: Alexander Drilon
Session: Poster session 01
628P - Efficacy and safety of larotrectinib as first-line treatment for patients (pts) with TRK fusion cancer: An updated analysis
Presenter: David Hong
Session: Poster session 01
629P - Phase I study of pamiparib and cabozantinib in patients with metastatic solid tumors harboring homologous recombination deficiency (HRD)
Presenter: Siqing Fu
Session: Poster session 01